Condition
Hilar Lymphadenopathy
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 4 (1)
Trial Status
Completed2
Withdrawn1
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05535439Not ApplicableCompleted
Diagnostic Yield & Specimen Adequacy of Flex 19 G vs 22 G EBUS Needle - A Randomized Controlled Trial
NCT05110950Not ApplicableUnknown
Endobronchial Ultrasound Needle Aspiration With and Without Suction
NCT03172832Not ApplicableTerminated
A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors
NCT01467635Not ApplicableWithdrawn
EBUS-TBNA Versus EBUS-TBNB
NCT01658280Phase 4Completed
Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
Showing all 5 trials